Core Points - A passenger transport public service contract was signed between the Ministry of Regional Development and Agriculture and OÜ TS Laevad for a seven-year period starting on 1 October 2026 [1] - TS Laevad will operate passenger transport services on the Virtsu-Kuivastu and Rohuküla-Heltermaa ferry routes using four of its own ferries and one additional state-owned ferry [2] - An amendment to the agreement allows the ferry Regula, owned by TS Laevad, to be used instead of the state-owned ferry until 31 December 2028 [3] - Regula is expected to make up to 800 trips per year from 1 October 2026 to 31 December 2028, with the Ministry paying both a fixed and variable fee for its use [4] - The contract amendment is seen as beneficial for TS Laevad and investors of the Port of Tallinn, providing stable income and return on assets [5] - Tallinna Sadam operates one of the largest cargo and passenger port complexes in the Baltic Sea region, with subsidiaries involved in ferry services and shipping [5]

MONTREAL, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Velan Inc. (TSX: VLN) (“Velan” or the “Company”), a world-leading manufacturer of industrial valves, announced today financial results for its third quarter ended November 30, 2025. All amounts are expressed in U.S. dollars unless indicated otherwise. THIRD-QUARTER HIGHLIGHTS FROM CONTINUING OPERATIONS IFRS MEASURES Sales of $71.7 million, versus $73.4 million last year.Gross profit of $27.2 million, or 37.9% of sales, compared to $28.3 million, or 38.6% of sales ...

Core Viewpoint - Velan Inc. announced the sale of approximately 72.1% of its outstanding shares to Birch Hill Equity Partners for C$13.10 per share, totaling approximately C$203.9 million, which is expected to enhance the company's growth potential and operational capabilities [1][3][6]. Group 1: Transaction Details - Velan Holding will sell 15,566,567 multiple voting shares and one subordinate voting share, representing about 72.1% of the company's outstanding shares and 92.8% of its voting rights [1]. - Following a pre-closing reorganization, the final sale will include 13,276,492 multiple voting shares and 2,290,076 subordinate voting shares, representing approximately 72.1% of the outstanding shares and 91.9% of voting rights [2]. - The transaction is expected to close in the first half of 2026, pending regulatory approvals and customary closing conditions [3]. Group 2: Strategic Implications - Birch Hill aims to maintain Velan's presence in Quebec and support its growth both locally and internationally [4]. - The partnership is expected to improve Velan's access to capital and strategic support, enhancing its competitive position globally [6]. - The Special Committee of independent directors recommended facilitating the transaction, indicating it is in the best interests of the company [7]. Group 3: Financial Considerations - Estimated transaction-related fees are approximately C$12 million, with additional change of control costs of about C$5 million [8]. - Velan has agreed to suspend dividend payments until the closing of the transaction or termination of the Cooperation Agreement [7]. Group 4: Governance Changes - An Investor Rights Agreement will be established, allowing Birch Hill to appoint up to four of seven nominees to the Board as long as they maintain over 40% of the voting rights [9]. - The Board size is anticipated to be reduced to seven members following the transaction [9]. Group 5: Company Background - Velan Inc. is a leading manufacturer of industrial valves, with sales of US$295 million in the last fiscal year and operations in nine countries [14]. - Birch Hill is a mid-market private equity firm with over C$6 billion in capital under management and a history of driving growth in its portfolio companies [15].

Core Insights - Ascentage Pharma Group International presented its achievements in 2025 and outlined its global innovation strategy for 2026 at the J.P. Morgan Healthcare Conference [1][2] Company Overview - Ascentage Pharma is a global, commercial stage biopharmaceutical company focused on developing novel therapies for unmet medical needs in cancer [9] - The company has a diverse pipeline that includes inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [9] Milestone Achievements - In 2025, Ascentage Pharma accelerated its global expansion, advancing product commercialization, clinical development, and pipeline innovation [2] - The company has established a strong foundation for sustained growth through its innovative engine in hematologic malignancies and solid tumors [2] Product Development - The two core products, Olverembatinib (a third-generation BCR-ABL inhibitor) and Lisaftoclax (a Bcl-2 inhibitor), are key growth drivers for 2026 [3] - Both products have shown significant progress in 2025 and are expected to generate a "dual-engine" effect for future growth [3] Clinical Studies and Innovations - Ascentage Pharma has made advancements in multiple clinical studies for its key drug candidates, presenting data at international academic congresses [4] - The company received IND clearance from the U.S. FDA for APG-3288, a novel BTK degrader, marking a significant step in targeted degradation [4][5] Pipeline Progress - The company is advancing several key clinical programs, including APG-5918 (EED inhibitor) and APG-2449 (FAK/ALK/ROS1 inhibitor), which are in various stages of clinical trials [6][7] - Multiple global registrational Phase III trials are progressing rapidly for its key products [5] Future Outlook - Potential milestones for 2026 include ongoing investigations of Olverembatinib, Lisaftoclax, and other pipeline candidates, which have not yet received FDA approval [8] - The company aims to continue its growth in commercial sales and expand patient accessibility across hospitals in China [12]

Core Viewpoint - Aya Gold & Silver Inc. announces the retirement of two long-standing Board members, Robert Taub and Dr. Jürgen Hambrecht, who will not seek re-election at the upcoming annual meeting, marking a significant transition in the company's governance [1][5]. Group 1: Board Member Contributions - Robert Taub has been on the Board for 10 years, serving as Chair since 2020, and has been pivotal in Aya's evolution and turnaround over the past five years, providing strategic leadership [2]. - Dr. Jürgen Hambrecht has served on the Board since 2019 and has played a key role in strengthening Aya's governance framework and advancing best practices [3]. Group 2: Shareholder Transactions - In connection with the Board transition, Taub and Hambrecht sold a total of 7.5 million shares, while remaining significant long-term shareholders of Aya [4]. - Management members sold approximately 1.1 million shares, representing about 12% of the executive management team's holdings, primarily from shares issued through long-term incentive plan options [4]. Group 3: Company Overview - Aya Gold & Silver is a Canadian precious metals mining company based in Morocco, focused on expanding its resource base and land package along the Anti-Atlas Fault, a geologically rich region [6]. - The company operates the Zgounder silver mine and is advancing the Boumadine polymetallic project, which has substantial mineral resources and significant exploration potential [7]. - Aya is committed to responsible mining and aims to deliver sustainable value for shareholders, employees, and host communities [8].

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued and outstanding common shares. At a Special Meeting of Stockholders held on April 16, 2025, shareholders approved a special resolution authorizing the Board of Directors, at any time prior to the next annual meeting of shareholders, to implement a share consolidation at a r ...

TORONTO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX; OTCQB:BSXGF) announces that the Federal Court of Altamira, Pará, Brazil, denied the Company’s request for recognition of provisional compliance with a prior judgment of the Federal Court of Appeals. That appellate judgment conditioned the effectiveness of the Construction License (Licença de Instalação – LI) for the Volta Grande Gold Project on (i) completion of the Indigenous Component Study based on p ...

With the proceeds from the offering, Innventure expects to fully repay all outstanding convertible debenturesORLANDO, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Innventure, Inc. (NASDAQ: INV) (“Innventure” or the “Company”), an industrial growth conglomerate, today announced that it has closed its previously announced registered direct offering of common stock to four institutional investors via a securities purchase agreement. The offering resulted in gross proceeds of approximately $40 million, before deduct ...

Operating Expenses Decline 4% Year-to-DateBalance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2026 ended November 30, 2025. Key Highlights: 1.Biomerica Expands Commercialization of inFoods® IBS Through Collaboration with Henry Schein During the second quart ...

CONWAY, Ark., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Home BancShares, Inc. (NYSE: HOMB) (“Home” or the “Company”), parent company of Centennial Bank, released quarterly earnings today. Quarterly Highlights MetricQ4 2025Q3 2025Q2 2025Q1 2025Q4 2024Net income$118.2 million$123.6 million$118.4 million$115.2 million$100.6 millionNet income, as adjusted (non-GAAP)(1)$117.9 million ...